ERBB2 is altered by amplification and/or overexpression in various cancer types, and antibodies that bind to the extracellular domain of HER2 are now standard-of-care in ERBB2 amplified breast and esophagogastric cancers42,43. This evidence concerns the gene ERBB2 and cancer.